Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. - Wikidata - awgldk - TriplyDB

Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis.

Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis.

http://www.wikidata.org/entity/Q37845734

about

Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer.A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.A phase 2 study of fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as a salvage treatment in patients with refractory or relapsed advanced gastric cancer.Comparative effectiveness and safety between oxaliplatin-based and cisplatin-based therapy in advanced gastric cancer: A meta-analysis of randomized controlled trials.TCRP1 expression is associated with platinum sensitivity in human lung and ovarian cancer cells.Capilliposide C Sensitizes Esophageal Squamous Carcinoma Cells to Oxaliplatin by Inducing Apoptosis Through the PI3K/Akt/mTOR Pathway.Capecitabine in gastric cancer.Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer.Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.Cisplatin or not in advanced gastric cancer: a systematic review and meta-analysis.Risk of thromboembolic events after perioperative chemotherapy versus surgery alone for esophageal adenocarcinoma Efficacy of paclitaxel-based doublet regimens combining with intraperitoneal chemotherapy for advanced gastric cancer with peritoneal metastasis.Efficacy and safety of docetaxel plus oxaliplatin as a first-line chemotherapy in patients with advanced or metastatic non-small cell lung cancer.Hyaluronan-Lysine Cisplatin Drug Carrier for Treatment of Localized Cancers: Pharmacokinetics, Tolerability, and Efficacy in Rodents and Canines.Management of advanced gastric cancer: An overview of major findings from meta-analysis.Oxaliplatin: a review of approved uses.Capecitabine for the treatment of gastric cancer.Seven-day capecitabine plus docetaxel and oxaliplatin regimen for the treatment of advanced gastric cancer: A phase-I clinical trial.Upregulation of microRNA-31 targeting integrin α5 suppresses tumor cell invasion and metastasis by indirectly regulating PI3K/AKT pathway in human gastric cancer SGC7901 cells.The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.The effect of curcumin on oxaliplatin and cisplatin neurotoxicity in rats: some behavioral, biochemical, and histopathological studies Gastric cancer: toward a cisplatin-free disease?QT interval prolongation and torsades de pointes with oxaliplatin.Downregulation of NPM expression by Her-2 reduces resistance of gastric cancer to oxaliplatin.Gastric cancer: clinical aspects, epidemiology and molecular background.High FAK combined with low JWA expression: clinical prognostic and predictive role for adjuvant fluorouracil-leucovorin-oxaliplatin treatment in resectable gastric cancer patients.Safety and efficacy of calcium and magnesium infusions in the chemoprevention of oxaliplatin-induced sensory neuropathy in gastrointestinal cancers.A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin.Topical application of acetic acid in cytoreduction of gastric cancer. A technical report using mouse model.Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer.Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery.Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study.MiR-29b reverses oxaliplatin-resistance in colorectal cancer by targeting SIRT1.Treatment with 20(S)-ginsenoside Rg3 reverses multidrug resistance in A549/DDP xenograft tumors.Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer?Target-specific delivery of oxaliplatin to HER2-positive gastric cancer cells in vivo using oxaliplatin-au-fe3o4-herceptin nanoparticles.

P2860

Q33399154-5FB33DB6-CF19-475E-A982-AFFD96DD9946 Q33399530-E3A2CCCD-7A4E-4B22-8AC9-335B1E44BC76 Q33416115-30D5C57C-BEEF-4413-85E4-6975315215EA Q33432145-4C516A07-462A-4568-B964-C17A32E52F46 Q33597683-B54579D7-E136-434A-87B2-77B4203ADFB8 Q33655965-1F019748-B323-4E67-8AB2-92939D66912F Q34236005-D5F0AA26-630F-4136-8769-44C76EF7750C Q34296389-17EE44CD-5B38-4CDE-8B81-D9EDC390A21C Q34658209-924AA87D-923D-4596-80BB-2420C27290EA Q35080136-5634CC07-A3C6-4FB9-BAE8-F32B89279CFE Q35691049-E1A03381-CF72-4AFD-96BC-B070BFA9CA6A Q36411935-17EB9D81-9045-46EE-BF7A-D083A62028A9 Q36439420-32400769-2064-4986-86A7-EA1FAECBAF8C Q36948510-AD381B6C-FE82-4BE4-991F-C386D951297E Q37718510-7FFD75B9-D99A-46AC-AB35-C769B8194303 Q37965616-B0832A71-DA43-4212-A5DF-571321F274C6 Q38608072-7EA5C348-7BA4-4370-B95D-BED9F25A44FB Q38729844-86D2FD85-77DF-4F0A-AB9B-7EE65F07F906 Q38806672-781E37DB-5D41-457F-97FD-34A100C3838D Q38941416-325EA714-EB63-4B31-A162-BCA611C2E906 Q42000475-60084782-B1B5-4811-969D-7801C7C6CF0D Q42125510-6196B94F-A4CB-4E4E-84A1-FAE740C1D70A Q42166906-5B0AB7F8-2A09-4E84-84DE-C150FCF7DB7F Q42290643-B63D09B5-E3C8-474F-B233-DE2B0D891C6A Q42615450-64D43ED7-64AF-43BE-BC4B-13EFF9EBDBFA Q43640344-EB9874DA-A715-403F-863F-DA58EA681A79 Q45837121-F4515360-255F-4039-AD00-CD1B6110821F Q45903506-A9129248-2171-41B5-8D44-0071046071DC Q48169930-8905AC4E-9F3C-42A5-80FD-628FFC11C87C Q50700149-D336B387-30AC-4908-8147-45E4E41B636B Q51137194-CB9B0B66-80A7-4B8F-B61F-7DCBA4854BC5 Q53190180-4F281DA4-D84A-4467-99B7-F3B78709C6C6 Q53701150-38024B57-1909-47C0-8A34-15D1BBFD3F6C Q53701964-9903EAB0-B59C-4E35-9D92-73C9266A3A6B Q54970742-23AB3C07-51F4-444E-A392-40C76A29AAAD Q55210424-CDAAB76B-C1F8-46B7-8717-E0EBA1C74F78

P2860

Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis.

http://www.wikidata.org/entity/Q37845734

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 February 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Effectiveness and safety of ox ...... atic review and meta-analysis.

@en

Effectiveness and safety of ox ...... atic review and meta-analysis.

@nl

type

label

Effectiveness and safety of ox ...... atic review and meta-analysis.

@en

Effectiveness and safety of ox ...... atic review and meta-analysis.

@nl

prefLabel

Effectiveness and safety of ox ...... atic review and meta-analysis.

@en

Effectiveness and safety of ox ...... atic review and meta-analysis.

@nl

P1433

Q37845734-9836771A-1A62-4753-A672-ADD86527F388

P1476

Q37845734-EAA35B7F-A7B2-4E2B-9B15-742A9684321F

P2093

Q37845734-22337833-549D-4148-8CFA-5A8C34FA991F

Q37845734-5EB4AF74-6838-4AD2-861A-19D32FADB201

Q37845734-71098306-FC09-4B12-8973-0EF27499F94C

Q37845734-71142752-7082-4727-9B36-68CCED607A2F

Q37845734-902D77A5-8005-4815-B661-27B73E03B332

P2860

Q37845734-29CC27A6-742A-4911-9402-E0EE44E159CD

Q37845734-30433C22-97BF-4F46-8FC6-E50669DD4B2B

Q37845734-43339E90-ED26-40ED-BBDF-FC3CE37E4499

Q37845734-4634F243-67BD-44E6-B915-C0482EE84203

Q37845734-6AC27FED-2D63-4DC3-AE7F-F3CA2452E01B

Q37845734-72BF88FE-C713-4970-8FEA-09D0068CFE45

Q37845734-76A66D5E-F302-48AB-B68F-9B2086D195A3

Q37845734-788C0F58-578A-4369-B1E0-2B7B8BB384B0

Q37845734-83BBE030-4CD9-4A19-9450-CAD153CE2133

Q37845734-87DCA873-8C95-4F18-9682-0673C65D9FD3

P2888

Q37845734-BDA7BD4E-2D48-4EEA-A328-311A953439AA

P304

Q37845734-4CD46F4D-B887-43DE-84AA-8C3CF3E5E3CF

P31

Q37845734-5842a24a-9ea6-4037-ad6d-b2da3721cdf0

Q37845734-6CC7CD16-378E-465B-862E-083DBC416A19

P356

Q37845734-1C231758-E3CF-4A14-BA60-376AA21177C4

P433

Q37845734-CB064915-CEEC-4B2E-93CF-E0D76174226D

P478

Q37845734-62B7B8BB-6E77-4778-9CF7-36FD670C90C0

P577

Q37845734-C1EA1D8E-68CA-44D9-98B8-E4A5DD56EFFE

P5875

Q37845734-DF112285-DED1-44FB-B943-85BEB4D87FC5

P698

Q37845734-932FAC0D-20EE-443B-B436-8AD43D35306A

P921

Q37845734-7C8150E4-8CA2-4C2C-8130-52E713D5B180

P356

S10120-011-0007-7

P1433

P1476

Effectiveness and safety of ox ...... atic review and meta-analysis.

@en

P2093

Camillo Aliberti

http://www.w3.org/2001/XMLSchema#string

Claudio Marinozzi

http://www.w3.org/2001/XMLSchema#string

Francesco Montagnani

http://www.w3.org/2001/XMLSchema#string

Giammaria Fiorentini

http://www.w3.org/2001/XMLSchema#string

Gina Turrisi

http://www.w3.org/2001/XMLSchema#string

P2860

The strengths and limitations of meta-analyses based on aggregate data

Global cancer statistics, 2002

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.

Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer.

Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.

Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Gr

Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.

P2888

s10120-011-0007-7

P304

50-55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10120-011-0007-7

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49854707

http://www.w3.org/2001/XMLSchema#string

P698

21340667

http://www.w3.org/2001/XMLSchema#string

P921